Less than Half of Fast-Tracked Cancer Drugs Show Benefits in Later Trials

• Many cancer drugs get accelerated FDA approval but don't prove benefits within 5 years • Accelerated approval program meant to give patients early access to promising treatments • Only 43% of cancer drugs with accelerated approval show clinical benefits in trials • Unclear how much patients understand about uncertainty of accelerated approval drugs
• FDA recently got more authority to withdraw accelerated approval for drugs not meeting commitments